Stocks TelegraphStocks Telegraph
Stock Ideas

VYNE Financial Statements and Analysis

NASDAQ : VYNE

VYNE Therapeutics

$0.57
0.0006+0.11%
At Close 4:00 PM
58.55
BESG ScoreESG Rating

FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateSep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20252025202520242024
periodQ3Q2Q1Q3Q2
revenue169.00K69.00K202.00K121.00K198.00K
cost of revenue00000
gross profit169.00K69.00K202.00K121.00K198.00K
gross profit ratio1.001.001.001.001.00
research and development expenses5.256M4.881M6.124M10.248M7.306M
general and administrative expenses02.73M3.275M2.964M3.288M
selling and marketing expenses00000
selling general and administrative expenses2.705M2.73M3.275M2.964M3.288M
other expenses00001.001M
operating expenses7.961M7.611M9.399M13.212M10.594M
cost and expenses7.961M7.611M9.399M13.212M10.594M
interest income00000
interest expense00000
depreciation and amortization6.00K6.00K6.00K01.001M
ebitda-7.42M-7.536M-9.191M-13.091M-9.395M
ebitda ratio-43.905-109.217-45.50-108.19-52.505
operating income-7.792M-7.542M-9.197M-13.091M-10.396M
operating income ratio-46.107-109.304-45.53-108.19-52.505
total other income expenses net366.00K1.795M594.00K934.00K1.001M
income before tax-7.426M-5.747M-8.603M-12.157M-9.395M
income before tax ratio-43.941-83.29-42.589-100.471-47.449
income tax expense000011.00K
net income-7.28M-5.755M-8.611M-12.157M-9.395M
net income ratio-43.077-83.406-42.629-100.471-47.449
eps-0.17-0.13-0.20-0.29-0.22
eps diluted-0.17-0.13-0.20-0.29-0.22
weighted average shs out42.745M42.759M42.673M42.587M42.586M
weighted average shs out dil42.745M42.759M42.673M42.587M42.586M
Graph

Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateSep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20252025202520242024
periodQ3Q2Q1Q3Q2
cash and cash equivalents19.346M22.047M28.209M16.272M29.655M
short term investments13.354M17.60M22.063M53.913M48.492M
cash and short term investments32.70M39.647M50.272M70.185M78.147M
net receivables00000
inventory00000
other current assets3.186M4.696M4.641M3.35M5.675M
total current assets35.886M44.343M54.913M73.535M83.776M
property plant equipment net96.00K134.00K169.00K122.00K151.00K
goodwill00000
intangible assets00000
goodwill and intangible assets00000
long term investments00000
tax assets00000
other non current assets149.999K241.00K1.341M2.541M2.721M
total non current assets245.999K375.00K1.51M2.663M2.872M
other assets00000
total assets36.132M44.718M56.423M76.198M86.648M
account payables1.197M1.414M3.534M3.986M4.516M
short term debt025.00K63.00K123.00K240.00K
tax payables00000
deferred revenue00000
other current liabilities2.847M4.397M8.694M8.552M6.998M
total current liabilities4.044M5.836M12.291M12.661M11.754M
long term debt000025.00K
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities00000
total non current liabilities000025.00K
other liabilities00000
capital lease obligations025.00K63.00K123.00K25.00K
total liabilities4.044M5.836M12.291M12.661M11.779M
preferred stock00000
common stock3.00K2.00K2.00K1.00K1.00K
retained earnings-752.816M-745.536M-739.781M-719.148M-706.991M
accumulated other comprehensive income loss4.00K-2.00K034.00K-58.00K
other total stockholders equity784.897M784.418M783.911M782.65M781.917M
total stockholders equity32.088M38.882M44.132M63.537M74.869M
total equity32.088M38.882M44.132M63.537M74.869M
total liabilities and stockholders equity36.132M44.718M56.423M76.198M86.648M
minority interest00000
total investments13.354M17.60M22.063M53.913M48.492M
total debt025.00K63.00K123.00K145.00K
net debt-19.346M-22.022M-28.146M-16.149M-29.51M
Graph

Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateSep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20252025202520242024
periodQ3Q2Q1Q3Q2
deferred income tax00000
stock based compensation487.00K529.00K763.00K734.00K885.00K
change in working capital-159.00K-5.369M-3.295M1.284M656.00K
accounts receivables1.633M1.074M-768.00K4.124M-2.83M
inventory00000
accounts payables-1.767M-6.406M-2.49M-2.909M3.521M
other working capital-25.00K-37.00K-37.00K69.00K-35.00K
other non cash items-150.00K-214.00K-324.00K2.77M-433.00K
net cash provided by operating activities-7.096M-10.803M-11.461M-8.51M-8.481M
investments in property plant and equipment00000
acquisitions net00000
purchases of investments-6.798M-9.575M-13.769M-28.424M-6.88M
sales maturities of investments11.20M14.25M33.60M23.60M25.90M
other investing activites00000
net cash used for investing activites4.402M4.675M19.831M-4.824M19.02M
debt repayment00000
common stock issued00011.00K0
common stock repurchased0-34.00K000
dividends paid00000
other financing activites-7.00K0-87.00K-13.00K-3.00K
net cash used provided by financing activities-7.00K-34.00K-87.00K-2.00K-3.00K
effect of forex changes on cash00000
net change in cash-2.701M-6.162M8.283M-13.336M10.536M
cash at end of period19.346M22.047M28.209M16.319M29.655M
cash at beginning of period22.047M28.209M19.926M29.655M19.119M
operating cashflow-7.096M-10.803M-11.461M-8.51M-8.481M
capital expenditure00000
free cash flow-7.096M-10.803M-11.461M-8.51M-8.481M
Graph

Frequently Asked Questions

How did VYNE Therapeutics Inc. do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, VYNE generated $169.00K in revenue last quarter, while its costs came in at $0.00.
Last quarter, how much Gross Profit did VYNE Therapeutics Inc. report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. VYNE Therapeutics Inc. reported a $169.00K Gross Profit for the quarter ended Sep 30, 2025.
Have VYNE's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. VYNE incurred $7.96M worth of Operating Expenses, while it generated -$7.79M worth of Operating Income.
How much Net Income has VYNE posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from VYNE Therapeutics Inc., the company generated -$7.28M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did VYNE Therapeutics Inc. have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to VYNE Therapeutics Inc. as of the end of the last quarter was $19.35M.
What are VYNE's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, VYNE had Total Net Receivables of $0.00.
In terms of Total Assets and Current Assets, where did VYNE Therapeutics Inc. stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of VYNE were $35.89M, while the Total Assets stand at $36.13M.
As of the last quarter, how much Total Debt did VYNE Therapeutics Inc. have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of VYNE's debt was $0.00 at the end of the last quarter.
What were VYNE's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, VYNE reported total liabilities of $4.04M.
How much did VYNE's Working Capital change over the last quarter?
Working Capital Change for VYNE was -$159.00K over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
VYNE generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. VYNE generated -$7.10M of Cash from Operating Activities during its recently reported quarter.
What was VYNE's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. VYNE reported a -$2.70M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph